Search

Now showing items 1-6 of 6

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

2019- Roe, M. T.; Li, Q. H.; Bhatt, D. L.; Bittner, V. A.; Diaz, R.; [et al.]

Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase

2023- Seijas Amigo, José; Salgado Barreira, Angel; Castelo Domínguez, Rosa Ana; Pérez-Álvarez, M.T.; Ponce-Piñón, B.; [et al.]

Differences Between Takotsubo and the Working Diagnosis of Myocardial Infarction With Nonobstructive Coronary Arteries

2022- López Pais, Javier; Izquierdo Coronel, B.; Raposeiras Roubín, Sergio; Álvarez Rodríguez, Leyre; Vedia, O.; [et al.]

Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World-MEMOGAL Study

2023- Seijas Amigo, José; Mauriz Montero, María José; Suarez Artime, Pedro; Gayoso Rey, Mónica; Estany Gestal, Ana; [et al.]

Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

2019- Steg, P. G.; Szarek, M.; Bhatt, D. L.; Bittner, V. A.; Bregeault, M. F.; [et al.]

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

2019- White, H. D.; Steg, P. G.; Szarek, M.; Bhatt, D. L.; Bittner, V. A.; [et al.]